Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Mirum Pharmaceuticals Inc

Healthcare US MIRM

92.49USD
0.66(0.71%)

Last update at 2026-06-04T20:00:00Z

Day Range

91.9295.25
LowHigh

52 Week Range

23.1435.56
LowHigh

Fundamentals

  • Previous Close 91.83
  • Market Cap1167.01M
  • Volume690427
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-93.31800M
  • Revenue TTM224.00M
  • Revenue Per Share TTM5.18
  • Gross Profit TTM 64.69M
  • Diluted EPS TTM-3.77

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -142.07100M -83.95100M -103.26400M -52.53200M -17.34800M
Minority interest - - - - 0.00000M
Net income -135.66500M -83.98800M -103.27000M -52.55300M -17.34800M
Selling general administrative 89.07M 59.22M 22.69M 11.75M 0.58M
Selling and marketing expenses - - - - -
Gross profit 64.69M 17.23M - - 0.00000M
Reconciled depreciation 3.68M 0.97M 0.62M 0.32M -
Ebit -131.22000M -173.41300M -104.29600M -55.06700M -4.37400M
Ebitda -126.99800M -64.65400M -102.92900M -54.74300M -
Depreciation and amortization 4.22M 108.76M 1.37M 0.32M -
Non operating income net other 4.22M -0.21600M 1.37M - 0.00000M
Operating income -131.22000M -173.41300M -104.29600M -54.74300M -17.40600M
Other operating expenses 208.28M 192.55M 104.30M 54.74M 0.00000M
Interest expense 15.98M 17.59M 0.34M 2.54M 0.00000M
Tax provision -6.40600M 0.04M 0.00600M 0.02M -
Interest income 3.86M 0.37M 1.56M 2.23M 0.06M
Net interest income -12.12200M -17.22400M 1.22M 2.23M -
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -6.40600M 0.04M 0.00600M 0.02M 0.00000M
Total revenue 77.06M 19.14M 0.00000M 0.00000M 0.00000M
Total operating expenses 195.91M 190.65M 104.30M 54.74M 4.37M
Cost of revenue 12.37M 1.90M - - 0.00000M
Total other income expense net -10.85100M 89.46M 1.03M 2.21M -21.64800M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -135.66500M -83.98800M -103.27000M -52.55300M -26.02200M
Net income applicable to common shares -135.66500M -83.98800M -103.27000M -52.55300M -26.02200M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 646.62M 352.91M 294.65M 240.86M 146.71M
Intangible assets 252.93M 58.95M 18.74M - -
Earning assets - - - - -
Other current assets 10.94M 8.95M 5.27M 4.53M 2.70M
Total liab 397.95M 210.87M 174.44M 68.77M 16.36M
Total stockholder equity 248.67M -392.82400M 120.21M -173.17100M -69.90100M
Deferred long term liab - - 0.20M - -
Other current liab 79.65M 55.11M 2.00M 1.26M 9.33M
Common stock 0.00500M 0.00400M 0.00300M 0.00300M 0.00200M
Capital stock 0.00500M 0.00400M 0.00300M 0.00300M 0.00200M
Retained earnings -556.23900M -392.82400M -257.15900M -173.17100M -69.90100M
Other liab - 144.88M 129.94M 47.68M 0.04M
Good will - - - - -
Other assets 0.00000M 101.38M 101.79M 3.22M 0.32M
Cash 286.33M 28.00M 31.34M 142.09M 139.95M
Cash and equivalents - - - - -
Total current liabilities 87.06M 64.73M 42.60M 18.46M 13.08M
Current deferred revenue -1.10400M - 30.72M 13.41M -
Net debt 21.82M -25.81500M -28.72600M -138.82300M -136.30400M
Short term debt 1.10M 0.93M 0.71M 0.64M 0.40M
Short long term debt - - - - -
Short long term debt total 308.14M 2.19M 2.61M 3.26M 3.65M
Other stockholder equity 803.26M 0.21M 377.40M -0.08600M -146.84300M
Property plant equipment - 0.91M 0.98M 1.29M 3.73M
Total current assets 387.54M 190.22M 166.59M 236.35M 119.36M
Long term investments - 0.00000M 4.98M 0.00000M 23.29M
Net tangible assets - 83.08M 101.47M 172.09M 130.35M
Short term investments 0.00000M 123.72M 125.20M 89.73M 104.69M
Net receivables 67.97M 23.99M 3.27M - -
Long term debt 306.42M - - - -
Inventory 22.31M 5.57M 1.51M - -
Accounts payable 7.42M 8.69M 9.17M 3.15M 3.35M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.64M -0.21700M -0.03500M 0.08M 0.13M
Additional paid in capital - - - - -
Common stock total equity - 0.00400M 0.00300M 0.00300M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - -392.82400M -257.15900M -173.17100M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.16M 101.38M 101.79M 1.27M 0.32M
Deferred long term asset charges - - - - -
Non current assets total 259.08M 162.68M 128.06M 4.51M 27.35M
Capital lease obligations 1.72M 2.19M 2.61M 3.26M 3.65M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 7.98M -42.42900M 11.34M -127.78100M -127.50000M
Change to liabilities 7.64M 22.66M 3.68M 10.06M 3.67M
Total cashflows from investing activities 7.70M 48.55M 37.87M -127.78100M -11.25000M
Net borrowings - - -0.15800M - 0.07M
Total cash from financing activities 109.09M 73.47M 181.29M 127.18M 89.75M
Change to operating activities -4.51400M -5.17700M -3.07200M -2.93500M -0.01800M
Net income -135.66500M -83.98800M -103.27000M -52.55300M -26.02200M
Change in cash -3.33700M -10.74600M 130.12M -39.99300M 77.94M
Begin period cash flow 131.34M 142.09M 11.97M 51.96M -
End period cash flow 128.00M 131.34M 142.09M 11.97M 51.96M
Total cash from operating activities -120.13600M -132.75800M -89.07500M -39.36200M -0.55950M
Issuance of capital stock 107.37M 9.01M 131.87M 127.18M -
Depreciation 3.68M 0.97M 0.62M 0.32M 0.32M
Other cashflows from investing activities - 91.00M 26.76M -127.50000M 108.00M
Dividends paid - 0.00000M - - 0.00000M
Change to inventory -3.44800M -0.49500M -0.49500M -0.49500M -0.49500M
Change to account receivables -20.72700M -20.72700M -20.72700M -20.72700M 0.00000M
Sale purchase of stock 15.59M 9.01M 131.87M 127.18M 59.79M
Other cashflows from financing activities -13.86500M 64.45M 49.42M 59.98M 49.42M
Change to netincome 27.01M 23.09M 12.55M 5.74M 21.81M
Capital expenditures 0.28M 19.02M 0.23M 0.28M 0.28M
Change receivables -20.72700M - - - 0.00000M
Cash flows other operating 3.52M 121.53M -2.41900M - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes -3.34900M -10.74500M 130.09M - 0.00000M
Change in working capital -21.05000M 16.98M 0.61M 7.12M -
Stock based compensation 27.01M 23.09M 12.55M 6.07M -
Other non cash items 12.47M -90.41000M 0.34M -0.32600M -
Free cash flow -120.41400M -151.78200M -89.30000M -39.64300M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MIRM
Mirum Pharmaceuticals Inc		 0.66 0.71% 92.49 - 104.17 6.20 4.64 6.31 -8.6176
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Mirum Pharmaceuticals Inc

950 Tower Lane, Foster City, CA, United States, 94404

Key Executives

Name Title Year Born
Mr. Christopher Peetz Pres, CEO & Director 1979
Dr. Ian Clements Chief Financial Officer 1969
Mr. Peter Radovich M.B.A., Ph.D. Chief Operating Officer 1978
Mr. Paul K. Ross Chief Compliance Officer NA
Ms. Erin Campany Sr. VP of HR 1968
Dr. Pamela Vig Ph.D. Head of R&D 1971
Ms. Lara Longpre MBA, MSC Chief Devel. Officer 1970
Ms. Vinita P. Kumar Sr. vice Pres of Quality NA
Mr. Christopher Peetz CEO & Director 1979
Mr. Peter Radovich M.B.A., Ph.D. COO & President 1978

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions